Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 18/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 15/20 | 0.39 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.38 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL500628 | 0.80 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1 | |
| SCHEMBL1864783 | 0.79 | HSP90AB1 (0.48) | HSP90AA1HSP90AB1 | |
| SCHEMBL1865627 | 0.78 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL1870789 | 0.75 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1HSP90B1TRAP1CYP1A2 | |
| SCHEMBL5002778 | 0.74 | HSP90AB1 (0.51) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL1867571 | 0.74 | HSP90AB1 (0.51) | HSP90AA1HSP90AB1 | |
| SCHEMBL501273 | 0.74 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1 | |
| SCHEMBL501439 | 0.73 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1PDK1 | |
| SCHEMBL500779 | 0.73 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1HSP90B1TRAP1PDK1 | |
| SCHEMBL1870020 | 0.73 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9539243-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2017-01-10 | — | — | US | disclosed |
| US-20150126499-A1 | Triazole Compounds that Modulate HSP90 Activity | SYNTA PHARMACEUTICALS CORP (US) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126499-A1 | Triazole Compounds that Modulate HSP90 Activity | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885HSP90B1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.